NeuroGrove Services
- Biofeedback Therapy
- Neurofeedback Therapy
- Ketamine Therapy
- Migraine Treatment
- Psychedelic Therapy
Arvada, CO
Arvada has a northwest Denver suburb with an outdoor-active demographic, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Olde Town, Candelas, and the Westminster border range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Lutheran Medical Center and St. Anthony network. The scene here skews toward clinics serving outdoor-active professionals and young families. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Arvada clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. During 2023 and 2024 the FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list, which limits 503A compounding pharmacies from sourcing those ingredients. Section 503A covers traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities that operate under cGMP standards.
The Colorado State Board of Pharmacy inspects compounding facilities for compliance with USP 795 and USP 797. Non-resident pharmacies must register with the state. Colorado has active medical spa and wellness clinic sectors, and the Board monitors peptide sourcing practices. Clinics should confirm that the compounding pharmacy they use carries a current Colorado permit and that any sterile preparation complies with current USP standards.